Response Pharma Completes Phase 2 Enrollment for RDX-002
Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a...
Category : Healthcare and Pharmaceutical
Cencora Expands Drug Shortage Program to Strengthen Supply Chain
Marks significant expansion of initiative to help health systems access critical, at-risk medications for patients Cencora, a global healthcare company, has significantly expanded the number...
Cadrenal Therapeutics Announces CMO Transition for Tecarfarin
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin...
Be Biopharma Publishes Study on Engraftment of Plasma Cells
Publication Demonstrates Engraftment of 20% of Infused Cells without Preconditioning with Consistent Distribution Upon Redosing Manuscript Published in the Molecular Therapy Journal Be Biopharma, Inc....
Lightbeam Health Wins Best in KLAS for Remote Monitoring
KLAS Research’s annual report recognizes Lightbeam Deviceless Remote Patient Monitoring® as the top vendor based on high customer satisfaction Lightbeam Health Solutions, the leader in...
Turn Therapeutics Achieves 24-Hour Live Vaccine Stability
Turn Therapeutics has successfully maintained a live vaccine’s viability for 24 hours at room temperature using its oil suspension technology. This breakthrough — which entailed...
Miist Therapeutics Secures $7M to Develop Fast-Acting Medicine
Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors including Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First,...
BenevolentAI Proposes Delisting via Merger with Osaka Holdings
Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces: Background and Reasons for Delisting Following the...
GATC Health’s Stem Cell Therapy Could Revolutionize Diabetes Care
Novel approach designed to offer a more personalized and effective treatment option for patients suffering from diabetes and potentially other diseases. GATC Health Corp., a...
Navega Therapeutics Gets CIRM Grant for Chronic Pain Treatment
Next-generation AAV gene therapy targets intractable chronic pain Navega Therapeutics, a biotechnology company developing epigenetic gene therapies, today announced the receipt of a $4M Translational Science grant...
China Medical University Pioneers AI-Driven Drug Discovery and CAR-T
Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world,...
Newronika Gets FDA IDE for U.S. Trial of Adaptive DBS System
Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption (IDE) from the U.S....
NABR Applauds CITES Decision on Cambodia’s Long-Tailed Macaques
The National Association for Biomedical Research (NABR) commends the CITES Standing Committee’s decision not to enact a trade suspension on long-tailed macaques (Macaca fascicularis) from Cambodia....
Nexalin DIFS™ Device Reduces Blood Pressure, Boosts Mental Health
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a...
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced...